📰 MaaT Pharma To Present Updated Preclinical Data at SITC (@sitcancer.bsky.social) 2025. We’re excited to share promising updated results for MaaT034 showing immune activation and anti-tumor activity in germ-free models. 👉 Full press release: www.maatpharma.com/november-5-2...

📰 [PressRelease] – We’re thrilled to announce that our Phase 3 results evaluating Xervyteg® (MaaT013) in acute Graft-versus-Host Disease (#aGvHD) have been selected for oral presentation at ASH Congress 2025. 👉 Read the full press release: www.maatpharma.com/november-3-2...

📄 [#PressRelease] - MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update 📍Next stops: SITC, SFGM-TC, Investir Day, ASH – see you there! 👉 Read the full press release: www.maatpharma.com/november-4-2...

📢 Proud to see our lead candidate MaaT013 highlighted in a new review in Current Opinion in Immunology by E. Godefroy and F. Altare, exploring how the gut microbiota regulates immune responses in acute graft-versus-host disease (#aGvHD). 🔬Open-access article: www.sciencedirect.com/science/arti...

📢 Meet Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, during the Annual Meeting of the SITC in National Harbor, Maryland, USA. 🔬 On Friday, November 7, Sheri will present our preclinical findings on MaaT034, our next generation co-cultured microbiome ecosystem therapy candidate.

Proud to share that MaaT013 (Xervyteg®) clinical data were featured in the latest special issue on acute Graft-versus-Host Disease (#aGvHD) in Current Opinion in Immunology. 🔗Open-access article here: sciencedirect.com/science/arti... #AlloHCT #Hematology

📢 Join MaaT Pharma as an 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗜𝗻𝘁𝗲𝗿𝗻 (𝗠/𝗙)! 📩 Interested? Send your CV and a short motivation email to [email protected] to apply now! 🔬 Full job description: www.maatpharma.com/wp-content/u... 🎓 6-month internship – starting early 2026 📍 Saint-Quentin-Fallavier (France)

📢 Join MaaT Pharma as an R&D Project Manager (M/F)! 🎯 Do you have strong project management experience in the pharmaceutical or biotech industry and a passion for innovation in oncology and microbiome research? This opportunity is for you! 🔬 Full job description: www.maatpharma.com/wp-content/u...

📢 [#Internship] – Join MaaT Pharma as a Quality Assurance Intern (M/F)! 📩 Interested? Send your CV and a short motivation email to [email protected] to apply now! 🔬 Full job description: www.maatpharma.com/wp-content/u... 📅 6-month internship – starting January/February 2026 📍 Lyon (France)

📢 Join MaaT Pharma as a Biological Collection Project Manager (M/F)! 📩 Send your resume and a short motivation email to [email protected] to apply now! 🔬 Detailed job description: www.maatpharma.com/wp-content/u... #ProjectManagement #Biotech #Microbiome #Production #Quality #Regulatory

📢 Noémie Laurent, Chargée des ressources humaines chez MaaT Pharma, et Michèle Boyer de Zordi, chargée de Mission RSE et HSE, seront présentes au Forum emploi des industries de santé 2025, le 9 octobre à Lyon. 👉 Contribuez à faire avancer la science du microbiote : www.forumemploi-industriessante.fr

📰 [PressRelease] - We’re proud to share that the DSMB has issued a positive recommendation following the second safety interim analysis of our Phase 2b PHOEBUS trial evaluating MaaT033 in patients receiving allo-HSCT. 👉 Read the full press release here: www.maatpharma.com/october-7-20...

Some keen Observations in Our October issue! 🦠 Cancer microbiome 🌊 Marine microbes in warming oceans 🌐 broad-range phages 🧬 genetically minimised Salmonella 🔧 Viral infection mechanisms 🧪 Oxaloacetate antiviral defence and more, here: www.nature.com/nmicrobiol/v...

Thinking about a postdoc in microbiome science? Our lab at the MPI for Biology (Tübingen) builds on the culture I established at Cornell: collaborative, creative, and internationally diverse. Postdocs lead their own projects with secure funding. Join us! #PostdocJobs #HostMicrobe #AcademicJobs

📅 Frederic Fasano, Directeur Stratégie et Développement Corporate chez MaaTPharma interviendra à la conférence annuelle du Musée de sciences biologiques Docteur Mérieux : « Vivre en Intelligences avec les Microbes ». 👉Plus d’informations : www.musee-docteur-merieux.com/conference-f...

📅 Emilie Plantamura, Directrice Médicale adjointe chez MaaT Pharma, interviendra lors du symposium « Développer une médecine du microbiote pour restaurer la symbiose hôte-microbes », organisé dans le cadre des Entretiens Jacques Cartier 2025. 👉Inscrivez-vous ici : www.billetweb.fr/developper-u...

📅 Join Eric Soyer, CFO at MaaT Pharma, and Guilhaume Debroas, our Head of Investor Relations, at the Portzamparc Groupe BNP Paribas’ digital Biotech & Health Seminar 2025, on October 1, 2025. #Biotech #Health #Investments #DigitalEvent #Investors #LifeSciences #Microbiome #Pharma #Portzamparc

🩸 To close #BloodCancerAwarenessMonth, we share a patient story on life-threatening #aGvHD after transplant, featured by Bloomberg with Dr. Loschi’s insights. 🎥 Watch the full story: youtu.be/P8pd0TlITpo?... At MaaT Pharma, we advance microbiome science to tackle unmet needs in hemato-oncology.

🎥 [Media] À l’occasion de la publication de nos résultats semestriels, notre Directeur Financier Eric Soyer est revenu sur nos derniers jalons créateurs de valeur pour Arnaud Bivès - Boursier.com. 👉 Lire l’interview complète : www.boursier.com/actions/actu...

📅 Meet Eric Soyer, Chief Financial Officer at MaaT Pharma, and Guilhaume Debroas, Head of Investor Relations at MaaT Pharma, at KBC Securities' Life Sciences Conference on Thursday, September 25, 2025, in Brussels. #IR #Investors #Finance #Microbiome #Innovation #Pharma #Science #Healthcare #KBC

🩸 For #BloodCancerAwarenessMonth, we spotlight the gut microbiome: a key player in immunity and cancer care. Microbiotherapies in trials aim to restore balance, boost treatment efficacy, and reduce post-transplant complications. 👉 Learn more: www.maatpharma.com/patients-car...

📢 [Euronext Indices] - MaaT Pharma (Euronext Paris: MAAT) has been included in the CAC Small, CAC Mid & Small, and CAC All-Tradable indices following the annual review of the Euronext Paris indices. #Euronext #Indices #CAC #Innovation #Microbiome #Oncology

📄 [Press release] - MaaT Pharma Publishes its Half Year 2025 Financial Results and Provides a Business Update 👉 Read the full press release for more information: www.maatpharma.com/september-17... #BusinessUpdate #FinancialResults #Oncology #Microbiome #aGvHD #Hematology

📅 [Event] – Join Guilhaume Debroas, Head of Investor Relations at MaaT Pharma, at the 8th edition of the #investor Forum Lyon Pole Bourse. 📍 Palais de la Bourse – Place de la Bourse, Lyon, France 🗓 September 23, 2025 #LyonPoleBourse #LyonForum2024 #InvestInBiotech #HealthcareInvestors

📅 Proud to sponsor the 16th edition of the #SFGMTC workshops on harmonizing practices in transplantation and cell therapy! Join Alex Kiss, our Medical Science Liaison, to discuss on innovative strategies to improve patient survival following allo-HSCT. 📍 Espace Inkermann Chatillon, Lille, France

🩸 #BloodCancerAwarenessMonth – Allo-HSCT can be life-saving, but may also cause #GvHD, a life-threatening complication. Standard treatments help many patients, yet resistance leaves unmet needs, driving research into microbiome-based therapies. 👉 Learn more here: www.maatpharma.com/patients-car...

🩸 September is #BloodCancerAwarenessMonth and we are joining the global effort to increase understanding of blood cancers. 👉 Want to learn more? Visit our dedicated page to discover information about blood cancer, bone marrow transplantation and stem cell donation: www.maatpharma.com/patients-car...

🎥 Dans une interview accordée à BFM Business, Frederic Fasano, Directeur Général Adjoint de MaaT Pharma, partage deux moments clés de ces derniers mois, et la stratégie qui guide l'entreprise. 👉 Découvrez l’échange complet avec @Erwan Morice : www.youtube.com/watch?v=XH9l... @bfmbusiness.bsky.social

📄 [Press release] – MaaT Pharma Secures €37.5 Million Loan From European Investment Bank @eib.org Marking a New Step in Advancing its Clinical Program in Hemato-Oncology 👉 For more information, read the full press release: www.maatpharma.com/july-28-2025...

📰 [Media] - MaaT Pharma featured in Citeline for advancing the potential world’s first hemato-oncology microbiota therapeutic! Thanks to Neena Brizmohun for highlighting Xervyteg® among the latest EU filings now under EMA review. 👉 Read the full article here: insights.citeline.com/pink-sheet/p...

We are pleased to announce a new exclusive long-term licensing, distribution and commercial agreement with Clinigen for our lead candidate Xervyteg® (MaaT013) for patients with acute Graft-versus-Host Disease (aGvHD) in Europe. 👉 www.maatpharma.com/july-2nd-202...

Massive audience for "The Microbiome's Influence on Cancer Therapy: Insights and Innovations" session at #ASCO2025 Bottom line: FMT (fecal matter transplant) works; probiotic supplements do not.

🦠 How Microbiome Research Is Transforming Medicine? To mark World Microbiome Day 2025, we spoke with Dr. Joël Doré, Research Director at INRAE, Scientific advisor, co-founder of MaaT Pharma, and one of the world’s leading microbiome experts. 👉 Read the interview: www.maatpharma.com/learn-more-a...

🎧 Proud to share our CEO Hervé Affagard is featured on Behind the Breakthroughs! He talks microbiome therapies for cancer, ALS & more. A must-listen on innovation, IA and microbiome! www.insideprecisionmedicine.com/multimedia/p... #Microbiome #Cancer #ALS #PrecisionMedicine #Podcast

🏆 Big news from Boston: MaaT Pharma wins Industry Disruptor of the Year at the Microbiome Movement Summit! Proud moment for our CEO Hervé Affagard and the whole team — a great recognition of our science and commitment to cancer patients. ✨ Thanks to the organizers! #MDDS2025 #Microbiome #EMIH #MTIG

📢 We're proud to announce that our CEO and co-founder and elected-president of EMIH, Hervé Affagard, MBA, Eng., will be speaking at the 10th Annual Microbiome Movement Summit starting today in Boston, MA, USA, until June 25. More information: microbiome-summit.com/whats-on/ful...

📄 [Press release] – MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025. 👉 For more information, read the full press release: www.maatpharma.com/june-19-2025... #BloodCancers #Cancer #aGvHD #Microbiome #MAA #EMA #Oncology #GeneralMeeting #Xervyteg #Business

🎥 Dans une interview accordée à Lyon Décideurs, Eric Soyer, Directeur Financier de MaaT Pharma, revient sur deux jalons majeurs récemment franchis par la Société. 👉 Retrouvez l’échange complet mené par Jean-Pierre Vacher dans Bourse & Valeurs : lyondecideurs.com/2025/06/vide...

📰 MaaT Pharma dans La Tribune ! Cet article revient sur notre demande d’AMM auprès de l’EMA pour Xervyteg® (MaaT013), évalué dans le traitement de l'aGvH. Si approuvé, cela sera une première en Europe pour un médicament microbiote ! 👉 Lire l'article : www.latribune.fr/innovation/2...

📅 Guilhaume Debroas, Head of Investor Relations at MaaT Pharma, will participate in the MID & SMALL CAPS 2025 Conference by Portzamparc Groupe BNP Paribas, on June 18-19 in Paris. 📍 Join us at the Étoile Business Center (21-25 Rue Balzac, 75008 Paris). #InvestorRelations #SmallCaps #MidCaps

📄 Proud to announce that updated positive data from the EAP for Xervyteg® will be presented by Prof Mohamad Mohty at the European Hematology Association (EHA) Congress today. The findings validate high efficacy observed in the ARES study in aGvHD. 👉 Press release: www.maatpharma.com/june-13-2025...

📢 We’re excited to join the European Hematology Association (EHA) 2025 Congress from June 12–15 in Milan, Italy! Meet our team on-site: 👨‍⚕️ Gianfranco Pittari, Chief Medical Officer at MaaT Pharma 🔬 Natalia Gemperle Ortiz, Global Medical Lead 📊 Salomé Biennier, Business Analyst 👉 shorturl.at/iymmE

[EN] - 🌍 On this World Environment Day, MaaT Pharma is proud to release its 2024 ESG Report! 👉 Discover our 2024 ESG report (French only): www.maatpharma.com/wp-content/u... #WorldEnvironmentDay #Environment #RSE #CSR #Sustainability #Innovation #Health #ESG #Oncology

📄 [Press release] – MaaT Pharma is proud to announce the submission of the Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (registered brand name of MaaT013) in Acute Graft-versus-Host Disease (#aGvHD). www.maatpharma.com/june-2-2025-...

📅 Proud to announce that Jonathan Chriqui, Chief Business Officer at MaaT Pharma, will present our latest advancements at the BIO International Convention 2025, taking place June 16–19 in Boston, USA. Don’t miss our Company Presentation: 🕐 Wednesday, June 18, 12:15 PM 📍 Room 153C #BIO2025 #BIOUS

📰 Media spotlight on MaaT034 in @pharmaphorum.bsky.social! Proud to be featured in pharmaphorum, in an article by Nicole Raleigh covering our latest preclinical data on MaaT034 presented at the AACR 2025 Annual Meeting. 👉 Read the full article: pharmaphorum.com/news/aacr-20... @theaacr.bsky.social

📢 World IBD Day - Another key study just dropped and it confirms the superiority of multidonor product over mono donor ones in Ulcerative Colitis! 👉Access the publication: link.springer.com/article/10.1... #Gastroenterology #IBD #UlcerativeColitis #Microbiota *IBD: Inflammatory Bowel Disease

🎥 Eric Soyer, CFO of MaaT Pharma, shares insights in an interview with La Bourse et la Vie TV about the key highlights of this year’s first quarter. 👉 Watch the full interview conducted by Didier Testot: www.labourseetlavie.com/strategies/p... #Investors #aGvHD #Immunology #Oncology #Microbiome

📄 [EHA2025] – MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress. 👉 Read the press release: www.maatpharma.com/may-14-2025-... #EHA #EAP #Phase3 #aGvHD #alloHSCT #Microbiome #Oncology #Cancer #Hematology

📄 [Press release] – MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025. If you’d like to know more, please read the press release: www.maatpharma.com/may-13-2025-... #BloodCancers #Cancer #aGvHD #Safety #Microbiome #FinancialResults #MAA #Oncology